source
- Amgen's daxdilimab shows 6-point CLASI-A reduction in phase 2 lupus trialAmgen reported data from its phase 2 study of the ILT7-targeting monoclonal antibody daxdilimab in patients with discoid lupus. The trial enrolled 72 patients and tested two dose levels. The lower…
- Massachusetts offers $40M in tax incentives to spur 1,600+ life-science jobsMassachusetts announced $40 million in tax incentives for 38 life‑science companies, targeting the creation of about 1,644 new jobs. Most of the companies-31 of them-will expand outside Boston and…